L. Dunn and A. Demichele, Genomic predictors of outcome and treatment response in breast cancer, Mol Diagn Ther, vol.13, pp.73-90, 2009.

C. M. Perou, T. Sorlie, M. B. Eisen, M. Van-de-rijn, and S. S. Jeffrey, Molecular portraits of human breast tumours, Nature, vol.406, pp.747-752, 2000.

T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, and S. Geisler, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, vol.98, pp.10869-10874, 2001.

Z. Hu, C. Fan, D. S. Oh, J. S. Marron, and X. He, The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, vol.7, p.96, 2006.

C. Sotiriou and L. Pusztai, Gene-expression signatures in breast cancer, N Engl J Med, vol.360, pp.790-800, 2009.

V. Gelsi-boyer, B. Orsetti, N. Cervera, P. Finetti, and F. Sircoulomb, Comprehensive profiling of 8p11-12 amplification in breast cancer, Molecular Cancer Research, vol.3, pp.655-667, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00158812

A. Bergamaschi, Y. H. Kim, P. Wang, T. Sørlie, and T. Hernandez-boussard, Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer, Genes Chromosomes Cancer, vol.45, pp.1033-1040, 2006.

F. Andre, B. Job, P. Dessen, A. Tordai, and S. Michiels, Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array, Clin Cancer Res, vol.15, pp.441-451, 2009.

K. Chin, S. Devries, J. Fridlyand, P. T. Spellman, and R. Roydasgupta, Genomic and transcriptional aberrations linked to breast cancer pathophysiologies, Cancer Cell, vol.10, pp.529-541, 2006.

N. Stransky, C. Vallot, F. Reyal, I. Bernard-pierrot, D. Medina et al., Regional copy number-independent deregulation of transcription in cancer, Nat Genet, vol.38, pp.1386-1396, 2006.

R. M. Neve, K. Chin, J. Fridlyand, J. Yeh, and F. L. Baehner, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol.10, pp.515-527, 2006.

J. Adéla?adéla?¨de, P. Finetti, I. Bekhouche, L. Repellini, and J. Geneix, Integrated profiling of basal and luminal breast cancers, Cancer Res, vol.67, pp.11565-11575, 2007.

S. F. Chin, A. E. Teschendorff, J. C. Marioni, Y. Wang, and N. L. Barbosa-morais, High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer, Genome Biol, vol.8, p.215, 2007.

A. Vincent-salomon, C. Lucchesi, N. Gruel, V. Raynal, and G. Pierron, breast cancer study group of the Institut Curie. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast, Clin Cancer, vol.14, pp.1956-1965, 2008.

L. Addou-klouche, J. Adéla?adéla?¨de, P. Finetti, N. Carbuccia, and A. Ferrari, Loss, mutation and deregulation of L3MBTL4 in breast cancers, Mol Cancer, vol.9, p.213, 2010.

H. M. Horlings, C. Lai, D. S. Nuyten, H. Halfwerk, and P. Kristel, Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients, Clin Cancer Res, vol.16, pp.651-663, 2010.

F. Sircoulomb, I. Bekhouche, P. Finetti, J. Adéla?adéla?¨de, B. Hamida et al., Genome profiling of ERBB2-amplified breast cancers, BMC Cancer, vol.10, p.539, 2010.

I. Bekhouche, P. Finetti, J. Adéla?adéla?¨de, A. Ferrari, and C. Tarpin, Highresolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes, PLoS ONE, vol.6, p.16950, 2011.

F. Sircoulomb, N. Nicolas, A. Ferrari, P. Finetti, I. Bekhouche et al., ZNF703 gene amplification at 8p12 specifies luminal B breast cancer, EMBO Mol Med, vol.3, pp.153-166, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01431945

N. G. Bediaga, A. Acha-sagredo, I. Guerra, A. Viguri, and C. Albaina, DNA methylation epigenotypes in breast cancer molecular subtypes, Breast Cancer Res, vol.12, p.77, 2010.

K. Holm, C. Hegardt, J. Staaf, J. Vallon-christersson, and G. Jönsson, Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns, Breast Cancer Res, vol.12, p.36, 2010.

I. Van-der-auwera, W. Yu, L. Suo, L. Van-neste, and P. Van-dam, Arraybased DNA methylation profiling for breast cancer subtype discrimination, PLoS One, vol.5, pp.12616-12625, 2010.

M. J. Fackler, C. B. Umbricht, D. Williams, P. Argani, and L. A. Cruz, Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence, Cancer Res, vol.71, pp.6195-6207, 2011.

V. K. Hill, C. Ricketts, I. Bieche, S. Vacher, and D. Gentle, Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity, Cancer Res, vol.71, pp.2988-2999, 2010.

H. Edgren, A. Murumagi, S. Kangaspeska, D. Nicorici, and V. Hongisto, Identification of fusion genes in breast cancer by paired-end RNA-sequencing, 2011.

, Genome Biol, vol.12, p.6

K. C. Ha, E. Lalonde, L. Li, L. Cavallone, and R. Natrajan, Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines, BMC Med Genomics, vol.4, p.75, 2011.

S. Banerji, K. Cibulskis, C. Rangel-escareno, K. K. Brown, and S. L. Carter, Sequence analysis of mutations and translocations across breast cancer subtypes, Nature, vol.486, pp.405-409, 2012.

, Comprehensive molecular portraits of human breast tumours, Cancer Genome Atlas Network, vol.490, pp.61-70, 2012.

M. J. Ellis, L. Ding, D. Shen, J. Luo, and V. J. Suman, Whole-genome analysis informs breast cancer response to aromatase inhibition, Nature, vol.486, pp.353-360, 2012.

S. P. Shah, A. Roth, R. Goya, A. Oloumi, and G. Ha, The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.486, pp.395-399, 2012.

P. J. Stephens, P. S. Tarpey, H. Davies, P. Van-loo, and C. Greenman, The landscape of cancer genes and mutational processes in breast cancer, Nature, vol.20486, pp.400-404, 2012.

T. B. Bédard and P. L. , Luminal-B breast cancer and novel therapeutic targets, Breast Cancer Res, vol.13, p.221, 2011.

T. Van-agthoven, A. M. Sieuwerts, J. Veldscholte, and M. E. Meijer-van-gelder, CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer, Br J Cancer, vol.101, pp.1824-1832, 2009.

T. Karn, E. Ruckhä-berle, L. Hanker, V. Müller, and M. Schmidt, Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance, Breast Cancer Res Treat, vol.130, pp.409-420, 2011.

T. Van-agthoven, M. F. Godinho, J. D. Wulfkuhle, E. F. Petricoin, and L. C. Dorssers, Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines, Int J Cancer, vol.131, pp.1998-2007, 2012.

S. Dadi, L. Noir, S. Payet-bornet, D. Lhermitte, L. Zacarias-cabeza et al., TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRa gene expression, Cancer Cell, vol.21, pp.563-576, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00739947

J. M. Flaman, T. Frebourg, V. Moreau, F. Charbonnier, and C. Martin, A simple p53 functional assay for screening cell lines, blood, and tumors, Proc Natl Acad Sci U S A, vol.92, pp.3963-3967, 1995.

P. Bertheau, E. Turpin, D. S. Rickman, M. Espié, and A. De-reyniès, Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen, PLoS Med, p.90, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00700961

L. M. Mcshane, D. G. Altman, W. Sauerbrei, S. E. Taube, and M. Gion, REporting recommendations for tumor MARKer prognostic studies (REMARK), Breast Cancer Res Treat, vol.100, pp.229-235, 2006.

M. Krzywinski, J. Schein, I. Birol, J. Connors, and R. Gascoyne, Circos: an information aesthetic for comparative genomics, Genome Res, vol.19, pp.1639-1645, 2009.

N. Deng, L. K. Goh, H. Wang, K. Das, and J. Tao, A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets, Gut, vol.61, pp.673-684, 2012.

C. H. Yeang, F. Mccormick, and A. Levine, Combinatorial patterns of somatic gene mutations in cancer, Faseb J, vol.22, pp.2605-2622, 2008.

M. N. Patel, M. D. Halling-brown, J. E. Tym, P. Workman, A. et al., Objective assessment of cancer genes for drug discovery, Nat Rev Drug Discov, vol.12, pp.35-50, 2013.

A. Bergamaschi, B. L. Christensen, and B. S. Katzenellenbogen, Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3f, FOXM1, and a gene signature associated with mitosis, Breast Cancer Res, vol.13, p.70, 2011.

I. Bernard-pierrot, N. Gruel, N. Stransky, A. Vincent-salomon, and F. Reyal, Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer, Cancer Res, vol.68, pp.7165-7175, 2008.

D. G. Holland, A. Burleigh, A. Git, M. A. Goldgraben, and P. A. Perez-mancera, ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium, EMBO Mol Med, vol.3, pp.167-180, 2011.

J. Zhang, X. Liu, A. Datta, K. Govindarajan, and W. L. Tam, RCP is a human breast cancer-promoting gene with Ras-activating function, J Clin Invest, vol.119, pp.2171-2183, 2009.

L. Braun, F. Mietzsch, P. Seibold, A. Schneeweiss, and P. Schirmacher, Intrinsic breast cancer subtypes defined by estrogen receptor signallingprognostic relevance of progesterone receptor loss, Mod Pathol, vol.26, pp.1161-1171, 2013.

G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, and M. G. Mastropasqua, Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse, Ann Oncol, vol.24, pp.661-668, 2013.

J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, and D. Voduc, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, vol.27, pp.1160-1167, 2009.

B. Weigelt, A. Mackay, A. 'hern, R. Natrajan, R. Tan et al., Breast cancer molecular profiling with single sample predictors: a retrospective analysis, Lancet Oncol, vol.11, pp.339-349, 2010.

H. Fang, L. Nie, C. Z. Liu, J. Guo, and D. , RecQL4 Helicase Amplification Is Involved in Human Breast Tumorigenesis, PLoS One, vol.8, p.69600, 2013.

S. Cornen, J. Adelaide, F. Bertucci, P. Finetti, and A. Guille, Mutations and deletions of ARID1A in breast tumors, Oncogene, vol.31, pp.4255-4256, 2012.

N. Turner, A. Pearson, R. Sharpe, M. Lambros, and F. Geyer, FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer, Cancer Res, vol.70, pp.2085-2094, 2010.

S. S. Kwek, R. Roy, H. Zhou, J. Climent, and J. A. Martinez-climent, Coamplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis, Oncogene, vol.28, pp.1892-1903, 2009.

E. Karlsson, M. A. Waltersson, J. Bostner, G. Pérez-tenorio, and B. Olsson, High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1, Genes Chromosomes Cancer, vol.50, pp.775-787, 2011.

, Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, 2013.

M. T. Teh, E. Gemenetzidis, D. Patel, R. Tariq, and A. Nadir, FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma, PLoS One, vol.7, p.34329, 2012.

S. Griffiths-jones, R. J. Grocock, S. Van-dongen, A. Bateman, and A. J. Enright, miRBase: microRNA sequences, targets and gene nomenclature, Nucleic Acids Res, vol.34, pp.140-144, 2006.

Q. C. Lau, E. Raja, M. Salto-tellez, Q. Liu, and K. Ito, RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer, Cancer Res, vol.66, pp.6512-6520, 2006.

B. Huang, Z. Qu, C. W. Ong, Y. H. Tsang, and G. Xiao, RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor a, Oncogene, vol.31, pp.527-534, 2012.

D. Accili and K. C. Arden, FoxOs at the crossroads of cellular metabolism, differentiation, and transformation, Cell, vol.117, pp.421-426, 2004.

Y. Zou, W. Tsai, C. Cheng, C. Hsu, and Y. M. Chung, Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis, Breast Cancer Research, vol.10, p.21, 2008.

H. O. Habashy, E. A. Rakha, M. Aleskandarany, M. Ahmed, and A. R. Green, FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer, Breast Cancer Research and Treatment, vol.129, pp.11-21, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00615379

W. A. Knight-3rd, C. K. Osborne, M. G. Yochmowitz, and W. L. Mcguire, Steroid hormone receptors in the management of human breast cancer, Ann Clin Res, vol.12, pp.202-207, 1980.

M. Ignatiadis and C. Sotiriou, Luminal breast cancer: from biology to treatment, Nat Rev Clin Oncol, vol.10, pp.494-506, 2013.

C. Y. Koo, K. W. Muir, and E. W. Lam, FOXM1: From cancer initiation to progression and treatment, Biochim Biophys Acta, vol.1819, pp.28-37, 2012.

M. Wang and A. L. Gartel, Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts, Mol Cancer Ther, vol.10, pp.2287-2297, 2011.